source
- Estuary debuts with $103M to develop kidney disease gene therapiesEstuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most common type of inherited kidney disease. Th…Endpoints · 4d ago↗ source
- FDA issues early alert for Edwards Lifesciences’ mitral valve delivery system after reported death, injuryThe FDA has issued an early alert for certain delivery systems used with Edwards Lifesciences’ SAPIEN M3 transcatheter mitral valve replacement system amid serious safety concerns.Fierce Biotech · 4d ago↗ source
- Vanda pauses social anxiety program after ex-Novartis asset flunks phase 3 studyA phase 3 trial of Vanda Pharmaceuticals’ social anxiety disorder drug candidate has missed its primary endpoint, prompting the company to put the program on hold.